ZB021 / InnoCare, Zenas BioPharma - LARVOL DELTA

ZB021, a novel oral, IL-17AA/AF inhibitor that blocks IL-17 AA homodimer and IL-17AF heterodimer signaling (The Manila Times) - "Dosing ongoing in Phase 1 trial of ZB021 in healthy volunteers....These data are expected by year-end 2026. Upon completion and evaluation of the SAD and MAD study, Zenas plans to initiate a proof-of-concept (POC) trial in North America to evaluate clinical activity and safety in psoriasis patients with results anticipated in 2027."

New trial • P1 data • Immunology • Psoriasis

The Board of Directors (the “Board”) is pleased to announce that the first subject has been dosed in the Phase 1 trial of ICP-054 (ZB021), a novel potentially best-in-class oral IL 17AA/AF inhibitor (InnoCare Pharma Press Release)

Trial status • Dermatology • Immunology • Rheumatology

Other pipeline updates (GlobeNewswire) - "Zenas expects initiation of Phase 1 clinical development for ZB021 in the second quarter of 2026 and to report initial clinical data by year-end 2026. Pending Phase 1 data, Zenas expects to advance development of ZB021 for rheumatic and/or dermatologic diseases....Zenas expects to complete IND enabling studies for ZB022 in 2026 and then advance the program into Phase 1 clinical development upon IND clearance."

New P1 trial • P1 data • Preclinical • Dermatology • Immunology • Inflammation • Rheumatology

Subject to Investigational New Drug (IND) clearance, Zenas expects to initiate Phase 1 clinical development for ZB021, a potentially best-in-class oral IL-17AA/AF inhibitor, in 2026 (GlobeNewswire) - "Pending Phase 1 data, Zenas expects to advance development of ZB021 for rheumatic and/or dermatologic diseases."

New P1 trial • Dermatology • Rheumatology

In Investigational New Drug (IND) enabling studies: Zenas expects to submit an IND and initiate Phase 1 clinical development in 2026. Pending Phase 1 data, Zenas expects to advance development of ZB021 for rheumatic and/or dermatologic diseases. (GlobeNewswire)

IND • New P1 trial • Dermatology • Rheumatology

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) - "Zenas also secured rights to a novel, oral, IL-17AA/AF inhibitor, and an oral, brain-penetrant, TYK2 inhibitor....Under the license agreement, Zenas will pay InnoCare upfront and near-term milestone payments of up to $100 million in cash, including milestone achievements expected in 2026, and up to 7,000,000 shares of Zenas common stock, including shares issuable upon a milestone expected to be achieved in early 2026."

Licensing / partnership • Multiple Sclerosis

A novel oral IL-17AA/AF inhibitor, and an oral, brain-penetrant, TYK2 inhibitor, expected to begin Phase 1 clinical trials in 2026 (GlobeNewswire)

New P1 trial • Immunology